The 2023 outbreak of viral conjunctivitis: Clinical features and treatment patterns from five states in India

Author:

Chatterjee Samrat12,Kapur Neha23,Chanda Sanjay24,Bhavatharini M.25,Sawant Sanil26,Sangwan Virender Singh23,Majumdar Atanu27

Affiliation:

1. Department of Cornea and Anterior Segment, MGM Eye Institute, Raipur, Chhattisgarh, India

2. Bodhya Eye Consortium, India

3. Department of Cornea and Anterior Segment, Dr. Shroff’s Charity Eye Hospital, New Delhi, India

4. Department of Cornea and Anterior Segment, CL Gupta Eye Institute, Moradabad, Uttar Pradesh, India

5. Department of Cornea and Refractive Surgery, Pushpagiri Vitreo Retina Institute, Secunderabad, Telangana, India

6. Department of Cornea and Refractive Surgery, Sadguru Netra Chikitsalaya, Chitrakoot, Madhya Pradesh, India

7. Department of Biostatistics, Dr. Shroff’s Charity Eye Hospital, New Delhi, India

Abstract

Background: In July 2023, an outbreak of viral conjunctivitis swept across India. A knowledge of clinical features and outcome of treatment helps in the management of future outbreaks. Aim: The aim of this study was to report the clinical presentation, treatment, and outcome in patients affected during the outbreak of viral conjunctivitis. Setting and Design: This was a multicentric retrospective case series. Materials and Methods: This study reviewed the medical records of all consecutive patients diagnosed with viral conjunctivitis between July 1, 2023, and August 10, 2023, in five centers across India. Results: Of the 793 patients, 525 (66.2%) were male and 268 (33.8%) were female, with a mean age of 34.1 ± 19.0 years. The mean symptom duration was 2.6 ± 2.1 days with bilateral disease in 591 (74.5%) patients. The common ocular signs were conjunctival congestion (793, 100%), lid edema (479, 60.4%), follicles (607, 76.5%), and conjunctival hemorrhages (339, 42.7%). Artificial tears were used in 730 (92.1%) patients, antibiotic eye drops in 661 (83.4%) patients, and steroid eye drops in 428 (54.0%). The time to resolution was the least in patients who had been treated with only artificial tears (4.61 ± 2.24 days) and was maximum in patients who had been treated with topical steroids (6.5 ± 2.51 days), and the difference was significant (P < 0.001). Conclusion: The presence of conjunctival hemorrhages indicated acute hemorrhagic conjunctivitis. Although many patients were treated with topical antibiotics, it was unnecessary, as the shortest resolution time was found in patients who had been received supportive therapy with artificial tear eye drops and not topical antibiotics or steroids.

Publisher

Medknow

Reference27 articles.

1. Virology and epidemiology analyses of global adenovirus-associated conjunctivitis outbreaks, 1953-2013;Zhang;Epidemiol Infect,2016

2. Unusual type of epidemic conjunctivitis in Ghana;Chatterjee;Br J Ophthalmol,1970

3. Joy Bangla. An epidemic of conjunctivitis in India;Pramanik;Practitioner,1971

4. Recent epidemic of acute haemorrhagic conjunctivitis in Calcutta;Baidya;Indian J Ophthalmol,1983

5. Acute hemorrhagic conjunctivitis, Key West, Florida. An assessment of risk factors for introduction of illness into households and secondary spread during the 1981 epidemic;Malison;Am J Epidemiol,1984

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3